The First Draft

2023-04-10

# 1 Introduction

Cardiovascular diseases (CVDs) is a group of disorders that affect the heart and blood vessels. CVDs are the leading cause of death globally, taking an estimated 17.9 million lives each year, representing 32% of all global deaths; Of these deaths, 85% were due to myocardial infarction (MI) (“Cardiovascular Diseases (CVDs)” n.d.). MI is a acute coronary syndrome in which sudden blockage of a coronary artery, and subsequent myocardial ischemia, leading to heart muscle damage or death (Yap et al. 2023).

Over the last 50 years, biomarkers are used in CVDs to facilitate diagnosis, assess risk, direct therapy and determine efficacy of CVDs treatment [BioH]. The latest universal definition of MI recognizes the importance of cardiac troponins (cTns) in detecting myocardial injury as a separate disease entity. However, the increased sensitivity of cTn assays has also led to more false positives (Thygesen et al. 2018), which require new definitions of pathological values. To improve upon existing biomarkers for CVDs, complementary biomarker combinations are being explored, including noncoding RNAs. Initial results suggest that MicroRNAs (miRNAs) may have potential as alternative and complementary biomarkers for CVDs (Schulte et al. 2020).

MiRNAs play a role in regulating gene expression. Research in various disease processes from cancer to cardiovascular disease has found that miRNAs play a role in disease pathogenesis and have potential as biomarkers and therapeutic agents or targets. Numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power (Schulte, Karakas, and Zeller 2017). They also have potential roles in the cardiovascular system, including angiogenesis, cardiac cell contractility, control of lipid metabolism, plaque formation, the arrangement of cardiac rhythm, and cardiac cell growth (Kalayinia et al. 2021). However, the function of miRNAs in CVDs extends beyond the myocardium. Their expression profiles can vary across various body fluids and subcellular groups, such as serum, plasma, and Peripheral Blood Mononuclear Cells (PBMCs) (Soler-Botija, Gálvez-Montón, and Bayés-Genís 2019).

PBMCs are a sub-population of white blood cells found in the peripheral blood, which include monocytes, lymphocytes, macrophages, and other cells that play a role in the immune system, therefore, they are important for understanding the functioning of the immune system (Gao et al. 2020). Multiple recent studies have used PBMCs as a source of biomarkers and have revealed alterations in mRNAs/miRNAs signature in different kinds of disorders. Recent studies revealed that PBMCs could recapitulate the conditions of the surrounding tissue, thus, providing a highly sensitive and specific source of biomarkers (Mosallaei et al. 2022). Moreover, there are reports of altered genes and miRNAs expression profile in CVDs in comparison to controls (Gao et al. 2020; Mosallaei et al. 2022).

The use of Machine Learning (ML) is an exciting prospect for advancing scientific discoveries. Although the concept of ML and its initial algorithms were conceived many years ago, recent improvements in computing power and access to vast amounts of data have shown that ML techniques outperform classical statistical methods in various fields. Furthermore, the progress made in omics technologies has enabled the analysis of massive and intricate biological data sets, consisting of hundreds to thousands of samples, which makes it possible for ML to extract valuable biological information from such data (Torun et al. 2023). Therefore, ML offers novel techniques to integrate and analyze the various omics data enabling the discovery of new biomarkers. These biomarkers have the potential to help in accurate disease prediction, patient stratification, and finding new therapeutic targets (Reel et al. 2021).

In this study, we aimed to identify potential miRNA biomarkers for MI patients by combining and analyzing three different microarray datasets from PBMCs. We believe that the integration of omics data with machine learning techniques could lead to the discovery of new and more accurate biomarkers for CVDs, including MI. This could provide insights into the underlying mechanisms of the disease and aid in the development of better diagnostic tools, patient stratification, and novel therapeutic targets.

# 2 Materials and Methods

## 2.1 Microarray data collection

Microarray datasets were obtained from the Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). To obtain sufficient classification power between MI samples and others, a relatively large sample size was required. Therefore, GSE59867 for MI and CAD samples, and GSE56609 and GSE54475 for healthy samples were selected. All samples were produced using Affymetrix Human Gene 1.0 ST Array (GPL6244) platform. Only healthy, stable CAD and early stage MI samples were selected from these datasets for further analysis. The basic information for the three datasets evaluated in the current study is provided in Table 2.1.

Table 2.1: Basic information of the GEO microarray datasets.

| Dataset | Platform | Healthy | CAD | MI | Refrence |
| --- | --- | --- | --- | --- | --- |
| GSE59867 | GPL6244 | - | 46 | 111 | (Maciejak et al. 2015) |
| GSE56609 | GPL6244 | 46 | - | - | (Matone et al. 2015) |
| GSE54475 | GPL6244 | 5 | - | - | (Canali et al. 2014) |

## 2.2 Pre-processing

Raw data (CEL files) of all datasets were downloaded from the GEO and pre-processed using the fRMA package (M. N. McCall, Bolstad, and Irizarry 2010). fRMA allowed to pre-process individual microarray samples and combine them consistently for analysis. For each dataset, background correction was performed using the RMA algorithm and then it was quantile normalized based on the reference distribution. During summarization, batch effects were removed and variances of the gene expressions were estimated by taking into account these probe-specific effects. For those multiple probe sets matched to the identical gene, the mean log fold change was retained. Therefore, fRMA can be seen as a batch effect removal technique for different datasets that produced by identical microarray platforms. Thus, to ensure batch effect removal, the principal component analysis and the relative log expression of train samples were plotted before and after fRMA (Lazar et al. 2013).

## 2.3 Differential expression analysis

The barcode algorithm proposed by McCall et al. (Matthew N. McCall et al. 2011) transformed the actual expression values into binary barcode values. Huge sets of samples were collected and normalized using fRMA for several platforms as well as for Affymetrix Human Gene 1.0 ST Array (GPL6244) platform. The distribution of the expressed and unexpressed observed intensities for each gene is estimated using these normalized sets. Genes were considered expressed (and their value coded to 1) or unexpressed (and their value coded to 0) according to the following equation:

where is the normalized intensity of gene in sample , is a user-defined parameter, is the standard deviation of the non-expressed distribution, and is the mean of the non-expressed distribution. The barcode representation of a sample is a vector of ones and zeros denoting which genes are estimated to be expressed (ones) and unexpressed (zeros). The barcode algorithm was implemented by the barcode function in the R fRMA package, and the default value of was used.

To determine if the expressed ratios differed in the MI group versus the healthy control group, Fisher’s exact test for individual genes was carried out upon the barcode values. Genes with a false discovery rate (FDR) of , which was calculated through the Benjamini-Hochberg (BH) procedure to adjust for multiple testing issues, were considered as differentially expressed genes.

The same procedures were conducted on CAD versus healthy controls as well as MI versus CAD group to find the DEGs between them.

## 2.4 Functional and pathway enrichment analyses

Using the R clusterProfilter package, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO) functional annotation were carried out on the differentially expressed genes. The GO analysis included biological process (BP), cellular component (CC) and molecular function (MF) categories. An adjusted p-value less than 0.05 was considered to indicate a statistically significant difference. Enrichments were conducted on the MI-healthy and CAD-healthy DEGs. In these analyses, all default parameters were used.

## 2.5 Machine Learning

The machine learning analysis was performed using Python software, ver. 3.9, numpy (Harris et al. 2020), pandas (McKinney 2010) and Scikit-Learn packages (Pedregosa et al. 2011). Whenever hyper-tuning was needed, the scikit-opt package (Head et al. 2021) was used. In all ML analysis, the datasets were divided into train and test sets by 0.7:0.3 ratio and all reported results are the average of 10-fold cross-validation.

Two different approaches were used for selecting miRNAs for model training. The first approach was using the miRNAs that are differentially expressed. In the second approach miRNAs were selected by their individual AUC-ROC. Having the result of these two different approaches can provide an informative comparison between the predictive capabilities of sets of miRNAs selected with different logics.

### 2.5.1 miRNAs in DEGs

In this approach, a two layer architecture was deployed to the data to maximize the prediction values. The first layer predicted whether a sample is healthy or not, and the second layer separated MI from CAD in the samples which were predicted as not healthy in the first layer. To this end, a distinct ML model was trained for each layer. Since there is a limited number of miRNAs in DEGs, both layers were trained with all of them. For further comparison with the models’ performance, ROC curve of each miRNA for classifying healthy and not-healthy, as well as CAD and MI, were generated using a Logistic Regression model.

#### 2.5.1.1 First layer for seperating healthy and not-healthy samples:

An SVM model using RBF kernels was trained and hyper-tuned using all miRNAs in DEGs. In order to handle the severe imbalance in the number of samples (51 for healthy and 157 for not-healthy group), sample weight for not-healthy samples was set to 0.5.

#### 2.5.1.2 Second layer for seperating MI and CAD samples:

For the sake of reaching the highest classification performance using the set of miRNAs, different models were investigated. To do so, SVM (with linear, polynomial, and RBF kernels), Logistic Regression (LR), Random Forests (RF), k-Nearest Neighbor (kNN), Gradient Boosting (GB), XGBoost (XGB) and Decision Tree (DT) models were trained. All models were trained with their pre-set parameters with 10-fold cross-validation.

The criteria for choosing the best model was the highest accuracy and AUC on the test set. The best model was hyper-tuned with the scikit-opt package (Head et al. 2021) to get the best predictive performance.

### 2.5.2 miRNAs with the highest AUC-ROC

Like the previous approach, a two layers strategy was conducted. The first layer classified samples into healthy and not-healthy, and the separated MI and CAD samples. However, to keep the number of miRNAs as low as possible miRNAs were selected from the second layer (which are the miRNAs with the best performance in MI/CAD separation), and then their performance wase evaluated in the first layer.

AUC-ROC of all miRNAs for classifying MI and CAD samples were calculated. To find the number of miRNAs with the highest predictive values, the miRNAs with the highest individual AUC-ROC were added to the set one-by-one, and the AUC-ROC for the set was calculated. The set with the highest AUC-ROC was selected for the following steps. The ROC curves for each selected miRNA for separating healthy samples from not-healthy and MIs from CADs were also plotted for further comparison.

#### 2.5.2.1 First layer for finding healthy and not-healthy samples:

An SVM model with an RBF kernel was trained using the selected set of miRNAs. Additionally, the model was hyper-tuned to find the hyper-parameters for the highest AUC and accuracy. The ROC curve and confusion matrix for the best model were reported.

#### 2.5.2.2 Second layer for separating MI and CAD:

The selected miRNAs set was used to train different algorithms to find the best model. Similar to the previous approach, SVM (with linear, polynomial, and RBF kernels), LR, RF, kNN, GB, XGB and DT were trained. All models were trained with their pre-set parameters using 10-fold cross-validation. The models with the highest AUC-ROC and accuracy on the test set were selected and hyper-tuned using the scikit-opt package (Head et al. 2021). The ROC curve and confusion matrix for the best model were reported.

# 3 Results

## 3.1 Pre-processing

The PCA plots of the training samples are shown in Fig3.1A and B. As is clear, there was complete separation between healthy samples and CAD or MI samples in primary data which remained after conducting fRMA on the data.

As Shown in the RLE plot for all samples before conducting fRMA (Fig3.1C) there was a distinct difference between datasets means. However, after conducting fRMA the means for all datasets were rearranged around 0 in the RLE plot (Fig3.1D). Moreover, there were a clear change in inter-quantile distances, but the values still was over 0.1.

![Figure 3.1: PCA and RLE plot for all samples before and after fRMA.](data:application/pdf;base64,)

Figure 3.1: PCA and RLE plot for all samples before and after fRMA.

## 3.2 Differential expression analysis

Table 3.1: Total, up-, and down-regulated DEGs and differentially expressed miRNAs.

DEGs

up-regulated DEGs

down-regulated DEGs

miRNAs

MI vs. Healthy

860

323

537

hsa-miR-186, miR-21, miR-32

CAD vs. Healthy

670

262

408

hsa-miR-186, miR-21, miR-32

MI vs. CAD

260

144

116

hsa-miR-186

According to the cutoff criterion of , there were 860 DEGs between the MI and the healthy samples. Among them, 323 were up-regulated, and 537 were down-regulated in MI compared to the healthy controls. For CAD and healthy groups there were 670 DEGs, 262 of which were up-regulated, and 408 of them were down-regulated in CAD samples in comparison with healthy samples. For the MI and CAD group the number of DEGs was 260, and the number of up- and down-regulated genes in MI samples in comparison with CAD samples were 144 and 116, respectively. All of these data is summarized in Table 3.1.




Figure 3.2: Venn diagram for DEGs in CAD/Healthy, MI/Healthy, and MI/CAD comparissons.

The Venn diagram in Fig3.2 shows that CAD and MI samples share a majority of their DEGs. From 860 DEGs of MI/healthy and 670 DEGs of CAD/healthy, 531 genes were common which is 62% of MI/healthy DEGs and 79% of CAD/healthy DEGs.

## 3.3 Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses of the DEGs.

To explore the biological classification of the DEGs, we performed GO and KEGG pathway enrichment analyses on MI-healthy and CAD-healthy DEGs.

For MI versus healthy samples, GO enrichment analysis in the BP category, suggested that the DEGs were enriched in “immune response-regulating signaling pathway”, “lymphocyte differentiation”, “immune response-regulating cell surface receptor signaling pathway”, and “leukocyte activation involved in immune response” (Fig3.3A). In the CC category the DEGs were enriched in “secretory granule membrane”, “azurophil granule”, “ficolin-1-rich granule”, “tertiary granule”, and “ficolin-1-rich granule membrane” (Fig3.3B). In the MF category, the DEGs were involved in “cadherin binding” and “MHC class I protein binding” (Fig3.3C). KEGG pathway analysis indicated that the DEGs were related to the following pathways: “Chemokine signaling pathway”, “Lipid and atherosclerosis”, and “Hematopoietic cell lineage” (Fig3.3D).

![Figure 3.3: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched with the MI and healthy DEGs. (A) Biological process terms. (B) Cellular component terms. (C) Molecular function terms. (D) KEGG analysis.](data:application/pdf;base64,)

Figure 3.3: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched with the MI and healthy DEGs. (A) Biological process terms. (B) Cellular component terms. (C) Molecular function terms. (D) KEGG analysis.

The enrichment results for DEGs of CAD versus healthy samples were as follows. In the BP category, GO enrichment suggested that the DEGs were enriched in “positive regulation of defense response”, “positive regulation of innate immune response”, “mononuclear cell differentiation”, and “positive regulation of response to external stimulus” (Fig3.4A). In the CC category the DEGs were enriched in “azurophil granule”, “ficolin-1-rich granule”, and “ficolin-1-rich granule membrane” (Fig3.4B). In the MF category, the DEGs were involved in “lipoprotein particle receptor binding” and “NF-B binding” (Fig3.4C). KEGG pathway analysis indicated that the DEGs were related to the following pathways: “Chemokine signaling pathway”, “Lipid and atherosclerosis”, and “Hematopoietic cell lineage” (Fig3.4D).

![Figure 3.4: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched with the CAD and healthy DEGs. (A) Biological process terms. (B) Cellular component terms. (C) Molecular function terms. (D) KEGG analysis.](data:application/pdf;base64,)

Figure 3.4: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched with the CAD and healthy DEGs. (A) Biological process terms. (B) Cellular component terms. (C) Molecular function terms. (D) KEGG analysis.

## 3.4 Machine Learning

### 3.4.1 miRNAs in DEGs

Among all DEGs, just miR-186, miR-32, and miR-21 were differentially expressed miRNAs. The expression profile of these three miRNAs is presented in Fig3.5. Additionally, The ROC curves of each miRNA for each layer are presented in Fig3.6. The AUC for miR-21, miR-32, and miR-186 was 0.99, 1, and 0.91 respectively using logistic regression model (Fig3.6A). Using the same model the accuracy of each miRNA for classifying the samples into healthy and not-healthy groups on the test set was 0.92, 0.98, and 0.89 for miR-21, miR-32, and miR-186 respectively. Moreover, in Fig3.6B the ROC curve of each miRNA for classifying MI and CAD samples was presented. For miR-21, miR-32, and miR-186, the AUC and accuracy on the test set was 0.85; 0.7; and 0.82, and 0.78; 0.67; and 0.74, respectively.

Table 3.2: Investigated miRNAs log fold-change and adjusted p-values for CAD samples relative to healthy, MI samples relative to healthy, and MI samples relative to CAD.

CAD/Healthy

MI/Healthy

MI/CAD

logFC

adj. p-value

logFC

adj. p-value

logFC

adj. p-value

miR-186

1.4

3.60e-25

0.9

6.76e-20

-0.5

1.05e-09

miR-21

1.4

1.31e-17

2.3

2.07e-47

0.8

2.96e-11

miR-32

2.5

8.39e-43

2.2

3.10e-59

-0.3

7.60e-04

miR-155

-0.6

2.49e-12

-0.9

7.59e-33

-0.2

2.68e-07

miR-142

0.2

1.90e-01

-0.1

1.70e-01

-0.3

2.90e-04

miR-197

0.5

2.95e-20

0.7

1.59e-47

0.2

8.58e-09

miR-29A

0.7

7.76e-29

0.1

1.70e-01

-0.5

2.14e-10

miR-320C1

0.8

4.72e-22

0.5

1.89e-30

-0.2

1.84e-05

![Figure 3.5: Expression profile of miR-186, miR-21, and miR32 in Healthy, CAD, and MI samples.](data:application/pdf;base64,)

Figure 3.5: Expression profile of miR-186, miR-21, and miR32 in Healthy, CAD, and MI samples.

![Figure 3.6: ROC curve for single miRNAs on test set classification for (A) healthy and not-healthy samples and (B) CAD and MI samples.](data:application/pdf;base64,)

Figure 3.6: ROC curve for single miRNAs on test set classification for (A) healthy and not-healthy samples and (B) CAD and MI samples.

#### 3.4.1.1 First layer for healthy not-healthy seperation:

Although single miRNAs had acceptable performance, their predictive value could be improved even further by using them as a set. The ROC curve for the SVM model with an RBF kernel trained with all three miRNAs is presented in Fig3.7A. The model had a better performance in classification than single miRNAs.The AUC for the model is 1, and its accuracy on test set was also 1. The confusion matrix for the model is presented in Fig3.8A.

![Figure 3.7: ROC curve for miRNAs in DEGs on test set classification for (A) healthy and not-healthy samples and (B) CAD and MI samples.](data:application/pdf;base64,)

Figure 3.7: ROC curve for miRNAs in DEGs on test set classification for (A) healthy and not-healthy samples and (B) CAD and MI samples.

![Figure 3.8: Confusion matrix on the test set for (A) An SVM model with RBF kernel for healthy and not-healthy samples classification. and (B) An SVM model with linear kernel for CAD and MI samples classification.](data:application/pdf;base64,)

Figure 3.8: Confusion matrix on the test set for (A) An SVM model with RBF kernel for healthy and not-healthy samples classification. and (B) An SVM model with linear kernel for CAD and MI samples classification.

#### 3.4.1.2 Second layer for separating MI samples from CAD:

Different models were trained using expression values of three differentially miRNAs. The models’ 10-fold cross-validated AUC and accuracy on the test set are reported on Fig3.9. The best model from both AUC and accuracy point-of-view was the SVM model with linear kernel. The AUC and accuracy for this model with its pre-set values was 0.93 and 0.82 respectively. The model was hyper-tuned for C and gamma hyper-parameters, and therefore the model showed better performance. The ROC curve of the hyper-tuned model is presented in Fig3.7B. For this model the AUC reached 0.95 and the accuracy improved to 0.85 (Table 3.3). Moreover, the sensitivity and specificity for the model on the test set were 0.91 and 0.71 respectively. The confusion matrix for the hyper-tuned model is illustrated in Fig3.8B.

![Figure 3.9: Area under curve (AUC) and accuracy of different models trained with three miRNAs in DEGs on the test set.](data:application/pdf;base64,)

Figure 3.9: Area under curve (AUC) and accuracy of different models trained with three miRNAs in DEGs on the test set.

Table 3.3: AUC-ROC and accuracy for SVM with linear kernel as the best model trained with differntially expressed miRNAs on the train and test set before and after hyper-tuning

Pre-set parameters

Hyper-tuned

Model

Metrics

train

test

train

test

SVM

AUC-ROC

0.91

0.93

0.92

0.95

(Linear Kernel)

Accuracy

0.83

0.82

0.84

0.85

### 3.4.2 AUC approach

After calculating the AUC for each miRNA in classifying MI and CAD samples, they were sorted, and their performance as a set was investigated. The metric of choice for selecting the best set was AUC. As shown in Fig3.10, the AUC increased until the number of miRNAs in the set reached six, and after that, it dropped. The AUC for separating MI samples from CAD using these miRNAs was 0.93. The miRNAs in the set were miR-29a, miR-197, miR-142, miR-21, miR-155, and miR-320C1. The expression values of these miRNAs in healthy, CAD, and MI samples is presented in Fig3.11. The ROC curve of the selected miRNAs for MI and CAD sample classification is illustrated in Fig3.6B.

![Figure 3.10: Area under curve (AUC) for sets containing increasing number of miRNAs with the highest individual AUC in MI/CAD separation.](data:application/pdf;base64,)

Figure 3.10: Area under curve (AUC) for sets containing increasing number of miRNAs with the highest individual AUC in MI/CAD separation.

![Figure 3.11: Expression profile of has-miR-29A, has-miR-197, has-miR-142, has-miR-21, has-miR-155, and has-miR-320C1 in Healthy, CAD, and MI samples.](data:application/pdf;base64,)

Figure 3.11: Expression profile of has-miR-29A, has-miR-197, has-miR-142, has-miR-21, has-miR-155, and has-miR-320C1 in Healthy, CAD, and MI samples.

#### 3.4.2.1 First layer:

Using the selected set, an SVM model with an RBF kernel was trained to separate healthy from not-healthy samples. The ROC curve for the model is presented in Fig3.12A and the confusion matrix is illustrated in Fig3.13A. Both AUC and accuracy for the model on the test set was equal to 1.

![Figure 3.12: ROC curve for the set of miRNAs selected by AUC on test set classification. (A) SVM with RBF kernel for healthy and not-healthy samples classification. (B) Logistic regression model for CAD and MI samples classification. (C) SVM with polynomial kernel for CAD and MI samples classification.](data:application/pdf;base64,)

Figure 3.12: ROC curve for the set of miRNAs selected by AUC on test set classification. (A) SVM with RBF kernel for healthy and not-healthy samples classification. (B) Logistic regression model for CAD and MI samples classification. (C) SVM with polynomial kernel for CAD and MI samples classification.

![Figure 3.13: Confusion matrix on the test set for (A) SVM with RBF kernel for healthy and not-healthy samples classification. (B) Logistic regression model for CAD and MI samples classification. (C) SVM with polynomial kernel for CAD and MI samples classification.](data:application/pdf;base64,)

Figure 3.13: Confusion matrix on the test set for (A) SVM with RBF kernel for healthy and not-healthy samples classification. (B) Logistic regression model for CAD and MI samples classification. (C) SVM with polynomial kernel for CAD and MI samples classification.

#### 3.4.2.2 Second layer; MI form CAD:

To find the best model for training the best set, different models were trained using their pre-set values. Their AUC and accuracy results on the test set are presented in Fig3.14. The best model from AUC point-of-view was the LR and from accuracy point-of-view it was the SVM model with a polynomial kernel. For the LR model the AUC and accuracy were 0.92 and 0.81, respectively; and for the SVM model with a polynomial kernel the values were 0.91 and 0.84, respectively. Both models were hyper-tuned and the ROC curve for their best performance presented in Fig3.12B and C. The AUC and accuracy for LR model increased to 0.94 and 0.88, respectively. For the SVM model with a polynomial kernel, these values increased to 0.95 and 0.88, respectively (Table 3.4). The sensitivity for the LR and SVM models were 1 and 0.97, respectively; and the specificity for them were 0.57 and 0.64, respectively. The confusion matrix for both models is illustrated in Fig3.13B and C.

![Figure 3.14: Area under curve (AUC) and accuracy of different models trained with three miRNAs in DEGs on the test set.](data:application/pdf;base64,)

Figure 3.14: Area under curve (AUC) and accuracy of different models trained with three miRNAs in DEGs on the test set.

Table 3.4: AUC-ROC and accuracy for SVM with linear kernel as the best model trained with miRNAs selected based on their individual AUC-ROC on the train and test set before and after hyper-tuning

Pre-set parameters

Hyper-tuned

Model

Metrics

Train

Test

Train

Test

LR

AUC-ROC

0.90

0.92

0.91

0.94

Accuracy

0.84

0.81

0.84

0.88

SVM

AUC-ROC

0.90

0.91

0.91

0.95

(Polynomial Kernel)

Accuracy

0.86

0.84

0.86

0.88

# 4 Discussion

AMI is a leading disease that threatens human life, but early diagnosis and treatment can reduce mortality and improve the prognosis of AMI (“Cardiovascular Diseases (CVDs)” n.d.; Thygesen et al. 2018; Tsao et al. 2022). Studies have suggested that changes in miRNA expression may play a significant role in the progression of MI and the subsequent remodeling (Laggerbauer and Engelhardt 2022), and this might occur during the various biological processes of MI in the myocardium or other related tissues (Khan, Gupta, and Mahapatra 2022).

Although the majority of researches have concentrated on examining free circulating miRNAs in the serum (Kaur et al. 2020), more information is needed to fully comprehend the miRNAs found in different blood sub-components like plasma, platelets, and PBMCs. PBMCs are critically involved in plaque destabilization and rupture as well as early inflammatory responses during myocardial infarction (Mosallaei et al. 2022; Hapke et al. 2022).

PBMCs have specific miRNAs that are altered under certain disease conditions, which are great candidates as disease biomarkers. The strength point of PBMCs’ miRNAs as biomarkers is early response of PBMCs to any drastic change in the body like MI on one hand (Mosallaei et al. 2022), and the regulatory role of miRNAs in cells, which leads to earlier changes in their expression profile compared to mRNAs and proteins on the other hand (Schulte et al. 2020). There are limited studies that compare the expression profiles of miRNAs in PBMCs from acute MI patients and healthy or CAD controls in order to find a robust set of miRNAs as biomarkers for MI. In this study, we combined three GEO datasets to include healthy, CAD, and MI samples. Having these samples set alongside each other allowed us to identify potential biomarker set and also effective therapeutic targets using both bioinformatics and machine learning means.

The results of DEG analysis (Table 3.1 and Fig3.2) are proof of the closeness among MI and CAD samples. Interestingly, functional enrichment analysis demonstrate that DEGs in both healthy/CAD and healthy/MI were strongly correlated to immune cell response which are a major part of PBMCs. Some analysis about the pathways …

Two different sets of miRNAs were used as biomarker sets for sample classification. miR-21; miR-32; and miR-186 were selected as differentially expressed miRNAs, and miR-21; miR-29a; miR-142; miR155; miR-197; and miR-320c1 were selected according to their AUC values. As shown in fig3.6, except for miR-142 and miR-29a all other miRNAs selected with both approaches had AUC-ROC over 0.9 in separating healthy and not-healthy samples; And as it is clear from this figure, the real challenge is in separating CAD from MI samples, which is because of their closeness as mentioned before. From 8 miRNAs under investigation, all of them except miR-32 had an AUC-ROC over 0.8 for classifying CAD and MI samples. The high AUC-ROC of miRNAs confirms their high potential as biomarkers.

Machine learning models were applied to miRNA sets selected by both DEG and AUC approaches, and they showed better performance in classification than single miRNAs. To avoid unwanted complexity, which may lead to poor predictive values, a two layer architecture was designed. The first layer was for separating healthy from not-healthy, and the second layer was for separating CAD from MI samples. As expected in both approaches, a hyper-tuned SVM model could flawlessly separates healthy from not-healthy samples using miRNAs sets. The machine learning models were also capable of effectively separating CAD from MI patients. Although both miRNA sets had nearly the same AUC-ROC with their best model, their accuracy, sensitivity, and specificity were different. The model trained with DEGs had better specificity, but the one trained with AUC-selected miRNAs had slightly better accuracy and higher sensitivity. This difference comes from the different logics we used for selecting the set of biomarkers.

Numerous studies reported different biological processes in PBMCs that these miRNAs are involved in, but there are still controversies regarding their exact role in immune system cells. Moreover, the activation of these miRNAs in PBMCs is also observed in cardiovascular events (S. Li et al. 2015; Yao et al. 2016; Liu et al. 2017; Horita, Farquharson, and Stephen 2021; Cai et al. 2020; Zhao et al. 2018; Bhansali et al. 2022). There is evidence that miR-186 suppresses the expression of Cystathionine--lyase, leading to subsequent promotion of secretion of pro-inflammatory cytokines and cellular lipid accumulation. This process suggest that macrophage-derived miR-186 may promote atherosclerosis (Yao et al. 2016). In complete accordance with this report, we found that miR-186 is up-regulated in both CAD and MI in comparison to healthy samples. Surprisingly, the expression of miR-186 is higher in CAD patients in comparison to MI (Fig3.5), and it is the only differentially expressed miRNA between these two groups, indicating its main role in atherosclerosis.

As mentioned before miR-21 was up-regulated in both MI and CAD in comparison to healthy samples. Moreover, the expression value of miR-21 was significantly higher in MI than CAD group according to Table 3.2. One of the main mechanisms that were reported for miR-21 in PBMCs is contribution to a diminished Treg cell population and following decrease in TGF secretion into the plasma through a TGF/smad-independent pathway. Therefore, our result is in complete agreement with previous findings about mir-21 role in PBMCs after cardiovascular events (S. Li et al. 2015).

Recently, it has been shown that miR-32 is up-regulated in CAD patients with coronary artery calcification. MiR-32 could be involved in calcification of vascular smooth muscle through bone morphogenetic protein-1, runt related transcription factor-2 (RUNX2), osteopontin, and bone-specific phosphoprotein matrix GLA protein, in mice vascular smooth muscle cells (Liu et al. 2017). Although, there are reports of mir-32 activation in PBMCs in different diseases (Zeng et al. 2021; Wang et al. 2020), its role in PBMCs after cardiovascular events was not studied extensively.

There are many reports indicating the role of miRNAs selected by AUC approach in PBMCs after a cardiovascular event. MiR-21 was the common element of two sets and covered earlier. MiR-29a is significantly up-regulated in CAD patients in comparison to both healthy and MI samples (Table 3.2). There are reports of its activity in different diseases (Horita, Farquharson, and Stephen 2021). Increased miR-29a levels were reported as a sign of atherosclerosis, and the combination of miR-29a and ox-LDL offered as a biomarker set for this disease (Huang et al. 2016). However, the role of miR-29a in PBMCs in CAD patient was not completely examined.

According to Table 3.2 difference in miR-142 expression between MI/Healthy and CAD/Healthy was not significant, but it was significant in between MI/CAD. Based on different reports, miR-142 is active in PBMCs. It directly targets and inhibits the expression of Adenomatous Polyposis Coli, a negative WNT signaling pathway regulator, contributing to the activation of WNT signaling pathway and cardiac fibroblast activation after MI (Cai et al. 2020).

In both approaches, miR-155 is the only down-regulated miRNA in all miRNAs between CAd and MI in comparison with healthy samples (Table 3.2). There are numerous reports on down-regulation of miR-155 in PBMCs after MI or in CAD patients and they suggests that the miR-155 levels can negatively related to the severity of coronary condition. (Zhang et al. 2015; Zhao et al. 2018). Combined with previous researches, we can conclude that miR-155 has a protective effect; miR-155 can control inflammation and reduce tissue damage through its negative feedback effects on inflammatory factors and inhibit the occurrence and development of atherosclerosis (Zhang et al. 2015).

MiR-197 is significantly up-regulated in both CAD/healthy and MI/healthy groups. In previous studies it has been shown that miRNA-197-5p may play a critical role in regulating the anti-inflammatory response of IL-35 by affecting pro/ anti-inflammatory cytokine secretion, M1/M2 macrophage ratio, Treg proliferation and T cell suppression, suggesting the potential diagnostic role of mir-197 in adverse cardiovascular events (Bhansali et al. 2022).

There are some reports about miR-320 role in cardiac fibrosis parthenogenesis. Mechanistically, downstream signaling pathway analyses revealed that miR-320 might induce various effects via targeting PLEKHM3 and IFITM1 in cardiomyocytes and cardiac fibroblasts, respectively (F. Li et al. 2021). However, there is no reports on miR-320c1 activity in cardiovascular system or PBMCs.

# Refrences

Bhansali, Shipra, Amit Kumar Yadav, Chetan Bakshi, and Veena Dhawan. 2022. “Interleukin-35 Mitigates Ox-LDL-Induced Proatherogenic Effects via Modulating miRNAs Associated with Coronary Artery Disease (CAD).” *Cardiovascular Drugs and Therapy*, April. <https://doi.org/10.1007/s10557-022-07335-x>.

Cai, Lidong, Gong Chao, Weifeng Li, Jumo Zhu, Fangfang Li, Baozhen Qi, Yong Wei, et al. 2020. “Activated Cd4+ T Cells-Derived Exosomal miR-142-3p Boosts Post-Ischemic Ventricular Remodeling by Activating Myofibroblast.” *Aging* 12 (8): 7380–96. <https://doi.org/10.18632/aging.103084>.

Canali, Raffaella, Lucia Natarelli, Guido Leoni, Elena Azzini, Raffaella Comitato, Oezgur Sancak, Luca Barella, and Fabio Virgili. 2014. “Vitamin C Supplementation Modulates Gene Expression in Peripheral Blood Mononuclear Cells Specifically Upon an Inflammatory Stimulus: A Pilot Study in Healthy Subjects.” *Genes & Nutrition* 9 (3): 390. <https://doi.org/10.1007/s12263-014-0390-x>.

“Cardiovascular Diseases (CVDs).” n.d. Accessed March 12, 2023. <https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)>.

Gao, Jie, Jia Liu, Ying Zhang, BaoYi Guan, Hua Qu, Hua Chai, WenTing Wang, XiaoJuan Ma, and DaZhuo Shi. 2020. “PBMCs-Derived microRNA Signature as a Prethrombotic Status Discriminator in Stable Coronary Artery Disease.” *Thrombosis and Haemostasis* 120 (01): 121–31. <https://doi.org/10.1055/s-0039-1700518>.

Hapke, Nils, Margarete Heinrichs, DiyaaElDin Ashour, Elena Vogel, Ulrich Hofmann, Stefan Frantz, and Gustavo Campos Ramos. 2022. “Identification of a Novel Cardiac Epitope Triggering T-Cell Responses in Patients with Myocardial Infarction.” *Journal of Molecular and Cellular Cardiology* 173 (December): 25–29. <https://doi.org/10.1016/j.yjmcc.2022.09.001>.

Harris, Charles R., K. Jarrod Millman, Stéfan J. van der Walt, Ralf Gommers, Pauli Virtanen, David Cournapeau, Eric Wieser, et al. 2020. “Array Programming with NumPy.” *Nature* 585 (7825): 357–62. <https://doi.org/10.1038/s41586-020-2649-2>.

Head, Tim, Manoj Kumar, Holger Nahrstaedt, Gilles Louppe, and Iaroslav Shcherbatyi. 2021. *Scikit-Optimize/Scikit-Optimize* (version v0.9.0). Zenodo. <https://doi.org/10.5281/zenodo.5565057>.

Horita, Masahiro, Colin Farquharson, and Louise A Stephen. 2021. “The Role of miR‐29 Family in Disease.” *Journal of Cellular Biochemistry* 122 (7): 696–715. <https://doi.org/10.1002/jcb.29896>.

Huang, Yu-Qing, An-Ping Cai, Ji-Yan Chen, Cheng Huang, Jie Li, and Ying-Qing Feng. 2016. “The Relationship of Plasma miR-29a and Oxidized Low Density Lipoprotein with Atherosclerosis.” *Cellular Physiology and Biochemistry* 40 (6): 1521–28. <https://doi.org/10.1159/000453202>.

Kalayinia, Samira, Fateme Arjmand, Majid Maleki, Mahshid Malakootian, and Chandra Pal Singh. 2021. “MicroRNAs: Roles in Cardiovascular Development and Disease.” *Cardiovascular Pathology* 50 (January): 107296. <https://doi.org/10.1016/j.carpath.2020.107296>.

Kaur, Amanpreet, Sharon T Mackin, Kenny Schlosser, Fui Lin Wong, Malik Elharram, Christian Delles, Duncan J Stewart, Natalie Dayan, Tara Landry, and Louise Pilote. 2020. “Systematic Review of microRNA Biomarkers in Acute Coronary Syndrome and Stable Coronary Artery Disease.” *Cardiovascular Research* 116 (6): 1113–24. <https://doi.org/10.1093/cvr/cvz302>.

Khan, Abrar A., Vinayak Gupta, and Nitish R. Mahapatra. 2022. “Key Regulatory miRNAs in Lipid Homeostasis: Implications for Cardiometabolic Diseases and Development of Novel Therapeutics.” *Drug Discovery Today* 27 (8): 2170–80. <https://doi.org/10.1016/j.drudis.2022.05.003>.

Laggerbauer, Bernhard, and Stefan Engelhardt. 2022. “MicroRNAs as Therapeutic Targets in Cardiovascular Disease.” *Journal of Clinical Investigation* 132 (11): e159179. <https://doi.org/10.1172/JCI159179>.

Lazar, C., S. Meganck, J. Taminau, D. Steenhoff, A. Coletta, C. Molter, D. Y. Weiss-Solis, R. Duque, H. Bersini, and A. Nowe. 2013. “Batch Effect Removal Methods for Microarray Gene Expression Data Integration: A Survey.” *Briefings in Bioinformatics* 14 (4): 469–90. <https://doi.org/10.1093/bib/bbs037>.

Li, Fang, Shan-Shan Li, Hui Chen, Jian-Zhi Zhao, Jie Hao, Jin-Ming Liu, Xiu-Guang Zu, and Wei Cui. 2021. “miR-320 Accelerates Chronic Heart Failure with Cardiac Fibrosis Through Activation of the Il6/Stat3 Axis.” *Aging* 13 (18): 22516–27. <https://doi.org/10.18632/aging.203562>.

Li, Sihui, Qian Fan, Shaolin He, Tingting Tang, Yuhua Liao, and Jiangjiao Xie. 2015. “MicroRNA-21 Negatively Regulates Treg Cells Through a TGF-/Smad-Independent Pathway in Patients with Coronary Heart Disease.” *Cellular Physiology and Biochemistry* 37 (3): 866–78. <https://doi.org/10.1159/000430214>.

Liu, Jianghua, Xinhua Xiao, Yingying Shen, Ling Chen, Canxin Xu, Heng Zhao, Ying Wu, et al. 2017. “MicroRNA-32 Promotes Calcification in Vascular Smooth Muscle Cells: Implications as a Novel Marker for Coronary Artery Calcification.” Edited by Yin Tintut. *PLOS ONE* 12 (3): e0174138. <https://doi.org/10.1371/journal.pone.0174138>.

Maciejak, Agata, Marek Kiliszek, Marcin Michalak, Dorota Tulacz, Grzegorz Opolski, Krzysztof Matlak, Slawomir Dobrzycki, Agnieszka Segiet, Monika Gora, and Beata Burzynska. 2015. “Gene Expression Profiling Reveals Potential Prognostic Biomarkers Associated with the Progression of Heart Failure.” *Genome Medicine* 7 (1): 26. <https://doi.org/10.1186/s13073-015-0149-z>.

Matone, Alice, Colm M. O’Grada, Eugene T. Dillon, Ciara Morris, Miriam F. Ryan, Marianne Walsh, Eileen R. Gibney, et al. 2015. “Body Mass Index Mediates Inflammatory Response to Acute Dietary Challenges.” *Molecular Nutrition & Food Research* 59 (11): 2279–92. <https://doi.org/10.1002/mnfr.201500184>.

McCall, M. N., B. M. Bolstad, and R. A. Irizarry. 2010. “Frozen Robust Multiarray Analysis (fRMA).” *Biostatistics* 11 (2): 242–53. <https://doi.org/10.1093/biostatistics/kxp059>.

McCall, Matthew N., Karan Uppal, Harris A. Jaffee, Michael J. Zilliox, and Rafael A. Irizarry. 2011. “The Gene Expression Barcode: Leveraging Public Data Repositories to Begin Cataloging the Human and Murine Transcriptomes.” *Nucleic Acids Research* 39 (suppl\_1): D1011–15. <https://doi.org/10.1093/nar/gkq1259>.

McKinney, Wes. 2010. “Data Structures for Statistical Computing in Python.” In *Proceedings of the 9th Python in Science Conference*, edited by Stéfan van der Walt and Jarrod Millman, 56–61. [https://doi.org/ 10.25080/Majora-92bf1922-00a](https://doi.org/ 10.25080/Majora-92bf1922-00a ) .

Mosallaei, Meysam, Naeim Ehtesham, Shima Rahimirad, Mostafa Saghi, Nasim Vatandoost, and Sharifeh Khosravi. 2022. “PBMCs: A New Source of Diagnostic and Prognostic Biomarkers.” *Archives of Physiology and Biochemistry* 128 (4): 1081–87. <https://doi.org/10.1080/13813455.2020.1752257>.

Pedregosa, F., G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, et al. 2011. “Scikit-Learn: Machine Learning in Python.” *Journal of Machine Learning Research* 12: 2825–30.

Reel, Parminder S., Smarti Reel, Ewan Pearson, Emanuele Trucco, and Emily Jefferson. 2021. “Using Machine Learning Approaches for Multi-Omics Data Analysis: A Review.” *Biotechnology Advances* 49 (July): 107739. <https://doi.org/10.1016/j.biotechadv.2021.107739>.

Schulte, Christian, Temo Barwari, Abhishek Joshi, Tanja Zeller, and Manuel Mayr. 2020. “Noncoding RNAs Versus Protein Biomarkers in Cardiovascular Disease.” *Trends in Molecular Medicine* 26 (6): 583–96. <https://doi.org/10.1016/j.molmed.2020.02.001>.

Schulte, Christian, Mahir Karakas, and Tanja Zeller. 2017. “microRNAs in Cardiovascular Disease – Clinical Application.” *Clinical Chemistry and Laboratory Medicine (CCLM)* 55 (5). <https://doi.org/10.1515/cclm-2016-0576>.

Soler-Botija, Carolina, Carolina Gálvez-Montón, and Antoni Bayés-Genís. 2019. “Epigenetic Biomarkers in Cardiovascular Diseases.” *Frontiers in Genetics* 10 (October): 950. <https://doi.org/10.3389/fgene.2019.00950>.

Thygesen, Kristian, Joseph S. Alpert, Allan S. Jaffe, Bernard R. Chaitman, Jeroen J. Bax, David A. Morrow, Harvey D. White, and The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. 2018. “Fourth Universal Definition of Myocardial Infarction (2018).” *Circulation* 138 (20). <https://doi.org/10.1161/CIR.0000000000000617>.

Torun, Furkan M., Sebastian Virreira Winter, Sophia Doll, Felix M. Riese, Artem Vorobyev, Johannes B. Mueller-Reif, Philipp E. Geyer, and Maximilian T. Strauss. 2023. “Transparent Exploration of Machine Learning for Biomarker Discovery from Proteomics and Omics Data.” *Journal of Proteome Research* 22 (2): 359–67. <https://doi.org/10.1021/acs.jproteome.2c00473>.

Tsao, Connie W., Aaron W. Aday, Zaid I. Almarzooq, Alvaro Alonso, Andrea Z. Beaton, Marcio S. Bittencourt, Amelia K. Boehme, et al. 2022. “Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association.” *Circulation* 145 (8). <https://doi.org/10.1161/CIR.0000000000001052>.

Wang, Dan, Ting Zeng, Zhi Lin, Lu Yan, Fenglin Wang, Lanlan Tang, Leyuan Wang, Daolin Tang, Pan Chen, and Minghua Yang. 2020. “Long Non-Coding RNA Snhg5 Regulates Chemotherapy Resistance Through the miR-32/Dnajb9 Axis in Acute Myeloid Leukemia.” *Biomedicine & Pharmacotherapy* 123 (March): 109802. <https://doi.org/10.1016/j.biopha.2019.109802>.

Yao, Yan, Xin Zhang, Hai-peng Chen, Liang Li, Wei Xie, Gang Lan, Zhen-wang Zhao, Xi-Long Zheng, Zong-bao Wang, and Chao-ke Tang. 2016. “MicroRNA-186 Promotes Macrophage Lipid Accumulation and Secretion of Pro-Inflammatory Cytokines by Targeting Cystathionine -Lyase in THP-1 Macrophages.” *Atherosclerosis* 250 (July): 122–32. <https://doi.org/10.1016/j.atherosclerosis.2016.04.030>.

Yap, Jonathan, Jason Irei, Javier Lozano-Gerona, Selena Vanapruks, Tianmai Bishop, and William A. Boisvert. 2023. “Macrophages in Cardiac Remodelling After Myocardial Infarction.” *Nature Reviews Cardiology*, January. <https://doi.org/10.1038/s41569-022-00823-5>.

Zeng, Zl, Qingyun Zhu, Zhibo Zhao, Xuyu Zu, and Jianghua Liu. 2021. “Magic and Mystery of microRNA‐32.” *Journal of Cellular and Molecular Medicine* 25 (18): 8588–8601. <https://doi.org/10.1111/jcmm.16861>.

Zhang, Yu-Hui, Liang-Hua Xia, Jia-Mei Jin, Ming Zong, Ming Chen, and Bo Zhang. 2015. “Expression Level of miR–155 in Peripheral Blood.” *Asian Pacific Journal of Tropical Medicine* 8 (3): 214–19. <https://doi.org/10.1016/S1995-7645(14)60318-7>.

Zhao, Duo, Jing Zhao, Jiangbin Sun, Yanling Su, Jinfeng Jian, Huaan Ye, Jiawang Lin, Zongda Yang, Jiatao Feng, and Zhiping Wang. 2018. “The Expression Level of miR-155 in Plasma and Peripheral Blood Mononuclear Cells in Coronary Artery Disease Patients and the Associations of These Levels with the Apoptosis Rate of Peripheral Blood Mononuclear Cells.” *Experimental and Therapeutic Medicine*, September. <https://doi.org/10.3892/etm.2018.6797>.